Author(s):
Gayathri H, Jefin Joby, Jomon Joy, Sibin C Babu, Jees Mariya K Babu, Adith A Amoor, Lakshminarayanan B
Email(s):
blnrxpharma@gmail.com
DOI:
10.52711/2231-5691.2025.00022 
Address:
Gayathri H, Jefin Joby, Jomon Joy, Sibin C Babu, Jees Mariya K Babu, Adith A Amoor, Lakshminarayanan B*
Department of Pharmaceutical Chemistry, Sanjo College of Pharmaceutical Studies, Vellapara, Palakkad, Kerala
*Corresponding Author
Published In:
Volume - 15,
Issue - 2,
Year - 2025
ABSTRACT:
Pyrazole derivative moiety exhibits diverse pharmacological characteristics, including anticancer properties, and serves as a foundational element for synthesizing various chemical compounds. This study aims to identify novel pyrazole-based chemical entities with anticancer potential and assess their binding capabilities through molecular docking analysis. Docking simulations were conducted using the receptor tyrosine protein kinase, known for its involvement in various human cancers such as lung cancer, thyroid cancer and breast cancer. Specifically, we focused on the G810A mutant of the RET protein domain (PDB ID: 6NE7). Among the compounds studied, EH15 (hydroxyl group at the m-position), EH49 (carboxylic acid group at the p-position), and EH52 (amide group at the p-position) exhibited remarkable binding energies. Notably, Compound EH32, containing an amino group at the o-position of the pyrazole derivative, demonstrated the highest binding affinity with the receptor and displayed significant inhibitory activity. These findings suggest that EH32 and other identified compounds could serve as potent inhibitors of the receptor tyrosine protein kinase, presenting promising avenues for anticancer drug development.
Cite this article:
Gayathri H, Jefin Joby, Jomon Joy, Sibin C Babu, Jees Mariya K Babu, Adith A Amoor, Lakshminarayanan B. Scrutinizing Pyrazole Derivatives as Potential Anticancer Agents: Molecular Docking Study on RET Protein Tyrosine Kinase. Asian Journal of Pharmaceutical Research. 2025; 15(2):134-0. doi: 10.52711/2231-5691.2025.00022
Cite(Electronic):
Gayathri H, Jefin Joby, Jomon Joy, Sibin C Babu, Jees Mariya K Babu, Adith A Amoor, Lakshminarayanan B. Scrutinizing Pyrazole Derivatives as Potential Anticancer Agents: Molecular Docking Study on RET Protein Tyrosine Kinase. Asian Journal of Pharmaceutical Research. 2025; 15(2):134-0. doi: 10.52711/2231-5691.2025.00022 Available on: https://asianjpr.com/AbstractView.aspx?PID=2025-15-2-7
REFERENCES:
1. Otmane B, Abdemoula A, Hamza G, Nabil B, Elmostfa F, Arnaud P et al. Synthesis, Anticancer Activities and Molecular Docking Studies of a Novel Class of 2-Phenyl-5,6,7,8-tetrahydroimidazo [1,2-b]pyridazine Derivatives Bearing Sulfonamides. Molecules. 2022; 27(16):5238. doi: 10.3390/molecules27165238
2. Sapkale GN, Khandare DD, Patil SM, Ulhas S Surwase. Drug Design: An Emerging Era of Modern Pharmaceutical Medicines. Asian J Res Chem. 2010; 3:261-4.
3. Thomas J. Bateman. Drug discovery. Science Direct. 2021; 4: 563-72. doi:10.1016/B978-0-12-819869-8.00019-7
4. Iqbal A. Molecular Docking in the Study of Ligand-Protein Recognition. Molecular Docking Recent Advances. 2023; 10:57772. doi:10.3390/md18110545
5. Simon ST, Tao S, Xuan L, Qingling H, Peng T, Mi Zhou et al. Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib. Biol. Chem. 2019; 294(27): 10428 –10437. doi 10.1074/jbc.RA119.007682
6. Ghaidaa HA, Thoraya AF, Magda HA. Indenyl-thiazoleandindenyl-formazan derivatives: Synthesis, Anticancer screening studies, molecular-docking, and pharmacokinetic/molin-spiration properties. Plos One. 2023; 18(3): e0274459. doi: 10.1371/journal.pone.0274459
7. Tanu K, Sana K, Kaneez F, Suaib L, Feroz K, Arvind SN. Synthesis, molecular docking and 2D-QSAR modeling of quinoxaline derivatives as potent anticancer agents against triple-negative breast cancer. Curr Top Med Chem. 2022; 22:855-867. doi:10.2174/ 156 8026622 666220324151808
8. Kai L, Xiang L, Hong-Jia Z, Juan S, Hai-Liang Z. Synthesis, molecular modeling and biological evaluation of 2-(benzylthio)-5-aryloxadiazole derivatives as anti-tumor agents. Eur J Med Chem. 2012; 47: 474-8. doi.org/10.1016/j.ejmech.2011.11.015
9. Monier AA, Melati K, Belal O. AN, Mohammad MA, Nik NSK, Mohamed K et al. EGFR Inhibitors and Apoptosis Inducers: Design, Docking, Synthesis, and Anticancer Activity of Novel Tri-Chalcone Derivatives. Sys Rev Pharm. 2021; 12(03):809-20. doi: 10.1016/j.bioorg. 2019.102997
10. Panneer Selvam T, Saravanan G, Prakash CR, Dinesh Kumar P. Microwave-Assisted Synthesis, Characterization and Biological Activity of Novel Pyrazole Derivatives. Asian J Pharm Res. 2011; 1(4):126-9.
11. Kedar MS, Shirbhate MP, Chauhan R, Sharma S, Verma A. Design Synthesis and Evaluation of Anticancer Pyrazole Derivatives of Chalcone Scaffold. Res J Pharm Tech. 2020; 13(1):342-6. doi: 10.5958/0974-360X.2020.00069.4.
12. Sharma A, Sharma GK, Chopra H. Synthesis and Biological Evaluation of Some Newer Pyrazole Derivatives. Res J Pharm Tech. 2021; 14(12):6304-8. doi: 10.52711/0974-360X.2021.01090.
13. Alam F. Synthesis and Biological Evaluation of Some Pyrazole-based Mannich Bases. Res J Pharm Tech. 2019; 12(9):4225-30. doi: 10.5958/0974-360X.2019.00726.1.
14. Shafi UK, Nafees A, Lay-Hong C, Rakesh N, Thet TH. Illustrated step by step protocol to perform molecular docking: Human estrogen receptor complex with 4-hydroxytamoxifen as a case study. Prog Drug Discov Biomed Sci 2020; 3(1): a0000054. doi.org/1 0.3687 /pddbs.a0000054
15. Jeffry D, Madura JA, Plumley TJ, Dick. A BBSI Tutorial. University of Pittsburgh. http://www.ccbb.p itt.edu/ BBSI/index.htm
16. Lakshminarayanan B, Christina AJM, Kannappan N, Vijayakumar B, Subburaju T. Desigining of ethoxy chalcones as potent anti-tumor agents by molecular docking process as an in-silico approach. AIJAST. 2021; 1(3):28 -36.
17. Kai-Cheng H, Yen-Fu C, Shen-Rong L, Jinn-Moon Y. iGEMDOCK: a graphical environment of enhancing GEMDOCK using pharmacological interactions and post-screening analysis. BMC bioinformatics. 2011; 12(1): S33. doi:10.1186/1471-2105-12-S1-S33.